OneSource CEO: Injectables to Dominate "Tremendous" GLP-1 Weight-Loss Market

• OneSource CEO Neeraj Sharma states injectables will continue to dominate the GLP-1 agonist weight-loss drug market, despite oral alternatives, citing a "tremendous" global opportunity of 1-1.5 billion potential patients.
• Bengaluru-based OneSource Specialty Pharma, India's first pure-play specialty pharma CDMO, is investing $100 million to expand its drug-device combination, injectable, and assembly capabilities.
• Delhi High Court's ruling allowing Semaglutide manufacturing/export for non-patented countries is "positive" for India; OneSource already manufactures the drug for clients awaiting approvals in markets like Canada (Jan 2026 patent expiry) and India (late March).
• Geopolitical trends like supply chain diversification and the US Biosecure Act significantly benefit Indian CDMOs due to their manufacturing base, expertise, cost efficiency, and compliance.
• GLP-1 market is expanding beyond diabetes/obesity to chronic kidney disease, liver disease, sleep apnea, and Alzheimer's, with injectables preferred over daily pills for weekly convenience.

Why It Matters: OneSource CEO predicts injectables will dominate the expanding GLP-1 market, boosting Indian CDMOs.